http://www.sciencedaily.com/releases...0514075710.htm

Remember that the spin meisters the drug companies use, are very good
at defusing doctors' questions. This was illustrated well during the Vioxx
incident.

My own doctor was led to believe that Liptor could REVERSE plaque. Which is totally untrue.

More scary data:
http://care.diabetesjournals.org/cgi...full/28/8/2082 from 2005

http://jech.bmj.com/cgi/content/abstract/58/12/1047

http://qjmed.oxfordjournals.org/cgi/.../full/97/4/229 personality changes

http://www.annals.org/cgi/content/full/139/9/792

http://www.tga.gov.au/adr/aadrb/aadr0504.htm

I personally agree with the one paper, that neuropathy presenting in diabetic patients may be misdiagnosed if a statin is being used as well. This would definitely increase the # of reports. After the patents are expired on Lipitor, I think we will see more data on the pitfalls of statins. Liability suits go the the patent holder (Pfizer) and typically in postmarketing situations, where danger exists, the original patent holder then releases negative data that they have been holding all along.